Search Results

BioSyent Inc. is pleased to announce that its wholly-owned subsidiary, BioSyent Pharma Inc., has entered into an agreement with a European partner for an exclusive license to register, market, sell and distribute a new endocrinology product in Canada.

BioSyent Inc. (“BioSyent”, “the Company”, TSX Venture: RX) is pleased to announce that its wholly-owned subsidiary, BioSyent Pharma Inc. (“BioSyent Pharma”), has extended its Exclusive License and Distribution Agreement with its European partner for the RepaGyn® and Proktis-M® products, extending BioSyent Pharma’s exclusive Canadian rights to these products until 2032.

BioSyent Inc. released its financial results for the three months ended March 31, 2024.

BioSyent Inc. is pleased to announce that its Board of Directors has declared a quarterly dividend of $0.045 per common share, payable in Canadian Dollars on June 15, 2024, to shareholders of record at the close of business on May 31, 2024.

BioSyent Inc. (“BioSyent”, TSX Venture: RX) is pleased to announce that it will be presenting at the upcoming 2024 Bloom Burton & Co. Healthcare Investor Conference.

BioSyent Inc. will be reporting its financial results for the three months ended March 31, 2024 on Thursday, May 16, 2024 after market hours.

BioSyent Inc. announces that Mr. René Goehrum, President and CEO of BioSyent, will be presenting in person at the LD Micro Invitational XIV Conference in New York City on Tuesday, April 9th at 8:00am EDT.

BioSyent Inc. (“BioSyent”, TSX Venture: RX) released today its financial results for the fourth quarter (Q4) and full year (FY) ended December 31, 2023.

BioSyent Inc. is pleased to announce that it has been named to the 2024 TSX Venture 50 list as one of the top performers on the TSX Venture Exchange.